Safety and efficacy of Certolizumab Pegol in a real-life cohort of patients with Psoriasis and Psoriatic Arthritis.

CONCLUSIONS: CZP was safe and effective in a real-life cohort of patients affected by PsO and PsA, who have had an inadequate response to previous systemic treatments. PMID: 30963798 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research